Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by jewel9mon Apr 06, 2016 8:01am

216 Views

Post# 24735466

RE:Pfizer to kill $160bn Allergan merger

Dachs1, i am a firm beleiver that the lead partner for the 1067 is Allergan and now that the Pfizer deal is over, there should not be an extended delay. Now Allergan does have a pendaing sale of its generic brands to Teva which is expected to close by June. We may see a delay until then, and Allergan will be cashed up with $40 billion from the sale.
Not sure if or when the compnay might PP and would like to hear if they did get the Wangbang payment yet.
If it is Allergan, the Pfizer deal being over is very positive for Sirona because Allergan will be looking for growth opportunities which Sirona has many.

Bullboard Posts

Optimi Health makes commercial entry into Australia